
Commentary|Videos|June 15, 2024
Dr Grunwald on the Rates of Disease Progression in Low-Risk Myelofibrosis
Author(s)Michael R. Grunwald, MD, FACP
Michael R. Grunwald, MD, FACP, discusses disease progression in patients with low-risk myelofibrosis enrolled in the prospective MOST study.
Advertisement
Michael R. Grunwald, MD, FACP, hematologist/ oncologist, chief, Leukemia Division; director, Transplantation and Cellular Therapy Program, Levine Cancer Institute, Atrium Health, discusses the rates and incidence of disease progression in patients with low-risk myelofibrosis who were enrolled in the prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST; NCT02953704).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































